Every Spin-Off
CSL Seqirus
Under reviewAUMakes seasonal and pandemic influenza vaccines, sold to governments, pharmacies and doctors, mainly in the US, UK and Europe.
CSL Seqirus is CSL's influenza vaccines business, one of the world's largest flu vaccine makers.
- Status
- Under review
- Expected
- Deferred indefinitely
- Parent
- CSL (CSL AU)
- Spin-off ticker
- To be announced
- Listing
- ASX
- Market
- Australia
- Sector
- Health care
Terms
In August 2025 CSL announced a demerger of Seqirus as a separate ASX-listed company, targeted by the end of FY26. On 28 October 2025 it deferred the demerger indefinitely because of falling US flu vaccination rates, and said timing would be revisited when market conditions support it. As of August 2026 there was still no confirmed date, although the operational separation of Seqirus was due by 1 July 2026.
Key dates
- Demerger announced with FY25 results
- Demerger deferred indefinitely
- Operational separation target
- Demerger timing
Source documents
- Press releaseFY25 results announcing Seqirus demerger (08/18/25)
- PresentationNot yet published
- Prospectus / demerger documentNot yet public
- Sourcebloomberg.com (deferral)
- Sourcekalkine.com.au (Aug 2026)
- Sourcefool.com.au (Aug 2026)
Every Spin-Off research
No report on this situation yet. New reports are published on Substack first.
Receive reports by email